Overview and Scope
Head and neck cancer diagnostics refers to the process of detecting and confirming the presence of malignant cells in the head and neck region by a combination of physical examination, imaging tests, medical history evaluation, and tissue biopsy. It is commonly used to treat squamous cell carcinomas, laryngeal cancer, and hypopharyngeal cancer.
Sizing and Forecast
The head and neck cancer diagnostics market size has grown rapidly in recent years. It will grow from $1.51 billion in 2023 to $1.79 billion in 2024 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to tobacco and alcohol consumption, increasing aging population, awareness campaigns, biopsy techniques development, healthcare infrastructure development.
The head and neck cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $3.32 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to genomic biomarkers, rising incidence of hpv-related cancers, integration of artificial intelligence (ai), immunotherapy and targeted therapies, healthcare policy and reimbursement changes. Major trends in the forecast period include liquid biopsy dominance, multi-modality diagnostics, point-of-care diagnostics, global collaborations and partnerships, digital pathology integration.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The head and neck cancer diagnostics market covered in this report is segmented –
1) By Diagnostic Method: Diagnostic Imaging Equipment, Endoscopy Screening Equipment, Biopsy Screening Tests, Dental Diagnostic Methods, Other Diagnostic Methods
2) By Channel: Retail and Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Diagnostic Centers, Other End Users
North America was the largest region in the head and neck cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12016&type=smp
Major Driver Impacting Market Growth
The increasing incidence of head and neck cancer is expected to propel the growth of the head and neck cancer diagnostics market going forward. Head and neck cancer is a group of tumors affecting the head and neck region’s tissues and organs. These malignancies include the mouth, pharynx, larynx, salivary glands, nasal cavity, and sinuses. Head and neck cancer diagnostics help head and neck cancer patients diagnose the disease early with various tests, including an incisional biopsy and a barium swallow test. For instance, in February 2023, according to the American Society of Clinical Oncology, a US-based professional organization for physicians and oncology professionals, Head and neck cancer made up 4% of all malignancies in the US. Head and neck cancer is predicted to affect 66,920 people in the USA in 2023 (49,190 men and 17,730 women). In 2020, head and neck cancer will affect 562,328 people worldwide. Furthermore, according to head and neck cancer in Australia statistics, there were 5,189 new head and neck cancer cases in 2022. Therefore, the rise in head and neck cancer incidence is driving the growth of the head and neck cancer diagnostics market.
Key Industry Players
Major companies operating in the head and neck cancer diagnostics market report are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Abbott Laboratories, Siemens Healthineers AG, BioNTech AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Laboratory Corporation of America, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Shimadzu Corporation, Sysmex Corp., Varian Medical Systems Inc., QIAGEN N.V., Exact Sciences Corp., Bio-Techne Corp., Carestream Health Inc., Myriad Genetics Inc., Cepheid Inc., Invitae Corporation, Accuray Inc., Canon Medical Systems Corporation, NanoString Technologies Inc, Asuragen Inc., Caris Life Sciences Inc., HTG Molecular Diagnostics Inc., Oncgnostics GmbH, Perseus Proteomics Inc., VolitionRx Ltd.
The head and neck cancer diagnostics market report table of contents includes:
- Executive Summary
- Head And Neck Cancer Diagnostics Market Characteristics
- Head And Neck Cancer Diagnostics Market Trends And Strategies
- Head And Neck Cancer Diagnostics Market – Macro Economic Scenario
- Global Head And Neck Cancer Diagnostics Market Size and Growth
.
.
.
- Global Head And Neck Cancer Diagnostics Market Competitive Benchmarking
- Global Head And Neck Cancer Diagnostics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Head And Neck Cancer Diagnostics Market
- Head And Neck Cancer Diagnostics Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model